[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620507":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":42,"responsibleParty":74,"collaborators":26,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":26,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":26,"enrollmentInfo":86,"targetDuration":26,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":98,"whyStopped":26,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Fudan University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Huaier Granules","EXPERIMENTAL","Take orally, 10g each time, three times a day. Participants in the experimental group should continue treatment for at least 24 weeks or until treatment failure, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; or until the investigator determines that there is no further benefit. For specific usage, refer to the drug instructions.",[13],"Drug: Huaier Granule",{"label":15,"type":16,"description":17,"interventionNames":18},"Anlotinib and Bevacizumab","ACTIVE_COMPARATOR","Administer according to clinical routine practice. Refer to the respective drug prescribing information for specific usage. Continue treatment until disease progression, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first.",[19],"Drug: Anlotinib and Bevacizumab",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Huaier Granule","Take orally, 10g each time, three times daily.",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Administer according to clinical routine practice. Refer to the respective drug prescribing information for specific usage.",[15],[31],{"name":32,"affiliation":5,"role":33},"Jialei Wang, phD","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":26,"email":38},"CONTACT","0086-18017312369","luwangjialei@126.com",{"name":40,"role":36,"phone":41,"phoneExt":26,"email":26},"Xinmin Zhao, phD","0086-18017312493",[43,60],{"facility":44,"status":26,"city":45,"state":46,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Xuzhou Central Hospital","Xuzhou","Jiangsu","China","CN",{"type":50,"coordinates":51},"Point",[52,53],117.28386,34.20442,{"lat":53,"lon":52},[56],{"name":57,"role":36,"phone":58,"phoneExt":26,"email":59},"Xiang Wang, phD","0086-18912007930","XiangWang7726@163.com",{"facility":61,"status":26,"city":62,"state":63,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine","Shanghai","Shanghai Municipality",{"type":50,"coordinates":65},[66,67],121.45806,31.22222,{"lat":67,"lon":66},[70],{"name":71,"role":36,"phone":72,"phoneExt":26,"email":73},"Fengfeng Han, phD","0086-13816386372","fengfhan86@sina.com",{"type":33,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Jialei Wang","Professor","100620507","phase-4-clinical-study-on-the-use-of-huaier-granules-for-the-treatment-of-proteinuria-related-to-bevacizumab-and-anlotinib-in-lung-cancer-patients-100620507",false,"NCT07358520","Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients","Prospective, Multicenter, Parallel-Controlled Clinical Study on the Use of Huaier Granules for the Treatment of Bevacizumab- and Anlotinib-Related Proteinuria in Lung Cancer Patients","Inclusion Criteria:\n\n* Age ≥18 years;\n* Histopathologically confirmed diagnosis of lung cancer;\n* Receiving Bevacizumab or Anlotinib treatment;\n* Positive urine protein detection, with 0.15g \\\u003C 24-hour urinary protein quantification \\\u003C 3.5g;\n* No treatment with Huaier Granules within one month prior to enrollment;\n* Expected survival time not less than 6 months;\n* Voluntary participation in this study and provision of signed informed consent.\n\nExclusion Criteria:\n\n* Known allergy, contraindication, or caution to any component of Huaier Granules;\n* Inability to take oral medication;\n* Required or ongoing use of drugs known to potentially affect proteinuria, including but not limited to ACE inhibitors, glucocorticoids (\\>3 weeks), and Chinese patent medicines (as per respective drug prescribing information);\n* Proteinuria caused by underlying diseases, including but not limited to nephropathy, hypertension, urinary tract infection, systemic lupus erythematosus, multiple myeloma, etc.;\n* Women who are pregnant, breastfeeding, or planning pregnancy;\n* Currently participating in other clinical trials investigating drugs for treating proteinuria;\n* Refusal to cooperate with follow-up;\n* Any other reasons deemed by the investigator as unsuitable for participation in this study.","ALL","18 Years",{"count":87,"type":88},40,"ESTIMATED","INTERVENTIONAL",[91],"PHASE4","This study is a prospective, multicenter, parallel-controlled clinical trial designed to evaluate the therapeutic efficacy of Huaier Granules for proteinuria occurring in lung cancer patients undergoing treatment with either Bevacizumab or Anlotinib.",[94],"Proteinuria",[9,94,96,97],"Bevacizumab","Anlotinib","NOT_YET_RECRUITING","2026-01-14",{"date":101,"type":102},"2026-01-22","ACTUAL",{"date":104,"type":88},"2026-01-28",{"date":106,"type":88},"2028-01-28",{"name":5,"class":6},2]